



# Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells

Simoun Icho,<sup>a,b</sup> Edurne Rujas,<sup>a,c,d,e</sup> Krithika Muthuraman,<sup>a,b</sup> John Tam,<sup>a</sup> Huazhu Liang,<sup>a,b</sup> Shelby Landreth,<sup>f</sup> Mingmin Liao,<sup>f</sup> Darryl Falzarano,<sup>f</sup> Jean-Philippe Julien,<sup>a,b,g</sup>  Roman A. Melnyk<sup>a,b</sup>

<sup>a</sup>Molecular Medicine Program, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada

<sup>b</sup>Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada

<sup>c</sup>Pharmacokinetic, Nanotechnology and Gene Therapy Group, Faculty of Pharmacy, University of the Basque Country UPV/EHU, Vitoria, Spain

<sup>d</sup>Ikerbasque, Basque Foundation for Science, Bilbao, Spain

<sup>e</sup>Biofisika Institute (CSIC, UPV/EHU), Bilbao, Spain

<sup>f</sup>Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

<sup>g</sup>Department of Immunology, University of Toronto, Toronto, Ontario, Canada

**ABSTRACT** An essential step in the infection life cycle of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the proteolytic activation of the viral spike (S) protein, which enables membrane fusion and entry into the host cell. Two distinct classes of host proteases have been implicated in the S protein activation step: cell-surface serine proteases, such as the cell-surface transmembrane protease, serine 2 (TMPRSS2), and endosomal cathepsins, leading to entry through either the cell-surface route or the endosomal route, respectively. In cells expressing TMPRSS2, inhibiting endosomal proteases using nonspecific cathepsin inhibitors such as E64d or lysosomotropic compounds such as hydroxychloroquine fails to prevent viral entry, suggesting that the endosomal route of entry is unimportant; however, mechanism-based toxicities and poor efficacy of these compounds confound our understanding of the importance of the endosomal route of entry. Here, to identify better pharmacological agents to elucidate the role of the endosomal route of entry, we profiled a panel of molecules identified through a high-throughput screen that inhibit endosomal pH and/or maturation through different mechanisms. Among the three distinct classes of inhibitors, we found that inhibiting vacuolar-ATPase using the macrolide bafilomycin A1 was the only agent able to potently block viral entry without associated cellular toxicity. Using both pseudotyped and authentic virus, we showed that bafilomycin A1 inhibits SARS-CoV-2 infection both in the absence and presence of TMPRSS2. Moreover, synergy was observed upon combining bafilomycin A1 with Camostat, a TMPRSS2 inhibitor, in neutralizing SARS-CoV-2 entry into TMPRSS2-expressing cells. Overall, this study highlights the importance of the endosomal route of entry for SARS-CoV-2 and provides a rationale for the generation of successful intervention strategies against this virus that combine inhibitors of both entry pathways.

**KEYWORDS** endosome, SARS, TMPRSS2, V-ATPase, virus

In December 2019 a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged causing a global public health crisis (1–4). The virus quickly spread across the world infecting, as of February 2022, over 430 million people across 220 countries and territories and leading to more than 5.9 million deaths (5). In early 2021, several vaccines were granted Emergency Use Authorization or approval by the U.S. Food and Drug Administration for their ability to induce an immune response and decrease SARS-CoV-2 infection. However, the emergence of several variants of

**Copyright** © 2022 Icho et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Roman A. Melnyk, roman.melnik@sickkids.ca.

The authors declare no conflict of interest.

**Received** 25 March 2022

**Returned for modification** 5 May 2022

**Accepted** 31 May 2022

**Published** 15 June 2022

concern with an altered antigenic profile, a higher infectivity, and a greater likelihood of death threaten the protective efficacy of current vaccines (6–9). In fact, several studies have already shown a reduction in neutralization potency against these variants by convalescent-phase serum and most monoclonal antibody therapies (10, 11). Hence, antiviral drugs are urgently needed to provide alternative therapeutic options but also as a safeguard against the emergence of new variants that are poorly managed by current vaccines.

The life cycle of SARS-CoV-2 provides numerous potential avenues for therapeutic intervention. Pfizer's Paxlovid and Merck's molnupiravir are two remarkable examples of antivirals that effectively stop viral replication by targeting viral proteins and significantly reducing the risk of hospitalization or death (12, 13). The SARS-CoV-2 replication cycle starts with the spike (S) protein binding to the cell-surface receptor angiotensin converting enzyme 2 (ACE2) (14, 15). Then, a cell-surface transmembrane protease, serine 2 (TMPRSS2) cleaves the S protein at the S1/S2 junction and activates the S2 domain (16–19). The activated S2 domain brings the viral membrane into close proximity to the cell membrane and initiates membrane fusion, which ultimately leads to the release of the viral genome into the host cell (20). Alternatively, upon ACE2 attachment the virus is endocytosed into endosomes where low-pH-activated proteases such as cathepsin B and cathepsin L activate the S2 domain, which similarly results in viral genome release but in this case through endosomal membrane fusion (21). Once the viral genome enters the host cytosol it begins propagating (20). Therefore, targeting any of these steps within the life cycle of SARS-CoV-2 would lead to neutralization of the virus.

Even though TMPRSS2 is expressed on lung and intestinal epithelial cells and, to a lesser extent, in the kidney, heart, adipose, and reproductive tissues, it is not found in other cells susceptible to SARS-CoV-2 infection (22, 23). Several studies have shown that inhibition of TMPRSS2 activity negatively affects the capacity of SARS-CoV-2 to infect host cells. However, the reported level of attenuation achieved by antivirals targeting TMPRSS2 vary depending on which cell line is used or which variant of SARS-CoV-2 is being tested (16, 24). More specifically, in the absence of TMPRSS2 expression or in the case of the Omicron variant, antivirals targeting TMPRSS2 are ineffective (16, 25). Further, Gunst et al. demonstrated in a randomized double-blind clinical trial that Camostat, a broad-spectrum serine protease inhibitor, did not reduce the time for clinical improvement, progression to intensive care unit admission, or mortality (26). Therefore, it is unlikely that a monotherapy strategy based on the use of antiviral drugs solely targeting TMPRSS2 will effectively stop viral replication.

Modulating endosomal pH using small molecules represents another attractive strategy that may be employed against SARS-CoV-2. The acidification of endosomes by vacuolar-ATPases (V-ATPases) is required for activation of cathepsin proteases, which are ubiquitous across all cells (27, 28). Although cathepsins represent attractive targets in a SARS-CoV-2 infection, potent and/or specific inhibitors of cathepsin B or cathepsin L proteases are not available (17–19). Furthermore, coronaviruses have been shown to utilize endosomal proteases other than cathepsins for viral activity (29, 30). Therefore, inhibiting endosomal acidification may represent an optimal strategy to fully neutralize SARS-CoV-2 infection. In fact, recent studies have shown that inhibition of endosomal acidification by using chloroquine or hydroxychloroquine is effective at neutralizing SARS-CoV-2 infection (31). Yet, the data cannot be replicated in TMPRSS2-expressing cells or translated to the clinic (32–34). Since both chloroquine and hydroxychloroquine are cationic amphiphilic compounds capable of inducing phospholipidosis, it is unclear which mechanism is operant when neutralizing SARS-CoV-2 infections *in vitro* (35). By specifically targeting V-ATPases, it may be possible both to neutralize SARS-CoV-2 infection and mitigate off-target effects.


In this study, we set out to investigate the importance of the endosomal pathway for SARS-CoV-2 entry using a collection of small molecule inhibitors of endosomal acidification identified from a high-throughput screen. We employed inhibitors using three

distinct mechanisms: (1) Lysosomotropic compounds, (2) Proton shuttle compounds, and (3) A direct V-ATPase inhibitor. Our results indicate that widely used nonspecific inhibitors of endosomal acidification are toxic at concentrations at which they neutralize the pH, which both confounds interpretation of the mechanism of SARS-CoV-2 inhibition and further portends clinical complications. In contrast, we found bafilomycin A1 to be uniquely potent and safe at inhibiting endosomal acidification and used it to investigate how infection by different variants of SARS-CoV-2 can be blocked by a safe and potent host-targeted mechanism inhibitor. Further, the combination of bafilomycin A1 and Camostat completely and synergistically neutralized SARS-CoV-2 entry into TMPRSS2-expressing cells without confounding cytotoxicity, opening the possibility of a new therapeutic modality that could be both effective and tolerable.

## RESULTS

**Inhibition of endosomal acidification blocks viral entry.** To address the importance of the endosomal route of entry for SARS-CoV-2 and identify diverse inhibitors of this pathway we developed a robust fluorescence-based high-throughput assay measuring endosomal acidification (Fig. S1A). We screened the MicroSource Spectrum collection of small molecules consisting of 2,560 approved drugs and pharmacologically active molecules with known targets and properties. The top 29 compounds (by percent inhibition) were initially selected for follow-up and tested across a 10-point dose titration for both inhibition of endosomal acidification and compound-mediated toxicity at 24 h (Fig. S2A). Among confirmed active compounds that dose dependently inhibited endosomal acidification, in all cases there was overlapping cellular toxicity seen at equivalent doses (Fig. S2B). To explore this further and determine whether this was a general feature of inhibitors of endosomal acidification, we selected a subset of compounds representing three distinct mechanisms of endosomal deacidification: (1) Lysosomotropic compounds amodiaquine, chloroquine, and quinacrine; (2) Proton shuttle compounds niclosamide and oxyclozanide; and (3) the direct V-ATPase inhibitor bafilomycin A1 (Fig. 1A). Each of the six compounds were tested for their ability to prevent endosomal acidification, viral entry, and cell viability. Antiviral activity was assessed initially using a pseudotyped virus approach in which the SARS-CoV-2 S protein was pseudotyped onto a human immunodeficiency virus-1 (HIV-1) backbone along with a luciferase reporter gene to measure viral infection (Fig. 1B) (36). Inhibition of the pseudoviral particle (PsV) by each compound was tested on HeLa cells expressing ACE2 (HeLa-ACE2). In parallel, each compound was also tested for its ability to inhibit endosomal acidification and its compound-mediated toxicity on HeLa-ACE2 cells over the same dose ranges.

A reduction in cell infection titers as well as inhibition of endosomal acidification was observed with the three lysosomotropic compounds at a similar concentration range (Fig. 1C). Specifically, the half-maximal inhibitory concentration ( $IC_{50}$ ) obtained for amodiaquine, chloroquine, and quinacrine was 2.5, 2.6, and 0.9  $\mu$ M, respectively. However, cell viability significantly decreased as cell infection titers was reduced. The half-cytotoxic concentration ( $CC_{50}$ ) measured for amodiaquine, chloroquine, and quinacrine was 34.7, 25.7, and 1.7  $\mu$ M, respectively, demonstrating a narrow window in which the compounds can be efficacious against PsVs without causing toxicity. Similarly, incubation of cells with niclosamide, a compound which shuttles protons out of acidified vesicles, at concentrations higher than 1  $\mu$ M resulted in no measurable infection and efficient endosomal acidification inhibition. However, at those concentrations, cell viability was severely affected ( $CC_{50}$  of 0.4  $\mu$ M). Oxyclozanide, on the other hand, did not alter infection levels nor endosomal acidification at concentrations up to 40  $\mu$ M but was toxic to cells with a  $CC_{50}$  of 18.7  $\mu$ M (Fig. 1C). Uniquely, bafilomycin A1 potently neutralized PsV entry into HeLa-ACE2 cells with an  $IC_{50}$  of 0.4 nM and inhibited endosomal acidification with an  $IC_{50}$  of 0.9 nM without displaying any associated cell cytotoxicity (Fig. 1C). Furthermore, additional toxicity measurements using Vero and Calu-3 cells confirm the above results (Fig. S3A and B). These findings highlight



**FIG 1** Identification of bafilomycin A1 as a safe and potent inhibitor of SARS-CoV-2 pseudovirus (PsV) entry into mammalian cells. (A) Chemical structure of three groups of endosomal acidification modifiers: lysosomotropic compounds (amodiaquine, chloroquine, and quinacrine), proton shuttles (Continued on next page)

fundamental differences among inhibitors of endosomal acidification on compound potency and compound-mediated cellular toxicity.

**Inhibition of either the cell-surface or endosomal entry mechanism attenuates viral entry.** In view of its uniquely potent and safe viral inhibition profile, we next sought to use bafilomycin A1 to investigate the relative importance of endosomal activation relative to cell-surface activation (37). A recent report by Hoffmann et al. concluded that endosomal acidification inhibitors, such as chloroquine, are incapable of neutralizing viral entry into cells expressing TMPRSS2 calling into question the importance of the endosomal pathway for viral propagation (32). For this purpose, we assessed the capacity of bafilomycin A1, alongside the control compound Camostat, to neutralize PsVs on cells expressing ACE2 and TMPRSS2 (Vero-TMPRSS2) and cells expressing ACE2 but lacking TMPRSS2 (HeLa-ACE2) (Fig. 2A). Consistent with previous reports, Camostat inhibited PsV entry into Vero-TMPRSS2 cells ( $IC_{50}$  of 252 nM) but was unable to inhibit PsV entry into HeLa-ACE2 cells lacking TMPRSS2 (32). In contrast, bafilomycin A1 potently inhibited PsV entry into HeLa-ACE2 cells with an  $IC_{50}$  of 0.4 nM and retained its neutralization potency when tested on Vero-TMPRSS2, albeit at slightly reduced potencies (*viz.*  $IC_{50}$  = 9.6 nM). In fact, bafilomycin A1 was 26-fold more potent than Camostat in stopping viral entry despite the presence of TMPRSS2. These findings are contrary from those reported previously for lysosomotropic molecules, which are suggested to be ineffective in TMPRSS2-positive cells, further highlighting the differences between endosomal inhibitors with distinct mechanisms of action (32).


To demonstrate that these observations were not cell-dependent, due to TMPRSS2 overexpression, or PsV-specific, we next assayed compound-induced neutralization in Vero cells, which naturally lack TMPRSS2 expression, and Calu-3 cells, which endogenously express TMPRSS2, using authentic SARS-CoV-2 viral particles. Importantly, the above results were reproduced with authentic SARS-CoV-2 viral particles (Fig. 2B). Consistent with what has been reported previously, Camostat significantly reduced SARS-CoV-2 infection titers in TMPRSS2-expressing Calu-3 cells but not in TMPRSS2-lacking Vero cells (32, 38). Bafilomycin A1, on the other hand, significantly reduced SARS-CoV-2 infection titers in both Vero and Calu-3 cells. Overall, while inhibition of either entry route effectively inhibits viral infection, inhibition of endosomal acidification via V-ATPase inhibition alone is effective at neutralizing SARS-CoV-2 entry irrespective of TMPRSS2 expression.

**Neutralization of SARS-CoV-2 variants of concern by Camostat and bafilomycin A1.** Next, we tested whether inhibition of SARS-CoV-2 cell entry by Camostat and bafilomycin A1 is affected by the different variants of the S protein that have emerged, since viral entry efficiency is different across different variants (39). Specifically, we compared the  $IC_{50}$  values of the two compounds against pseudoviruses containing four distinct S proteins: D614G (Wild type), B.1.1.7 (*i.e.*, Alpha), B.1.351 (*i.e.*, Beta), B.1.1.529 (*i.e.*, Omicron). Camostat inhibited the entry of wild type, Alpha, and Beta variants into Vero-TMPRSS2 cells; however, was unable to inhibit the entry of the Omicron variant into Vero-TMPRSS2 cells nor, as expected, stop viral infection of any of the variants when tested on HeLa-ACE2 cells lacking TMPRSS2 expression (Fig. 3A). These findings reinforce the notion that the relative importance of each entry pathway differs among variants and that the Omicron variant relies more heavily on the endosomal route for entry into cells (25). Consistent with this, bafilomycin A1 inhibited viral entry of all the variants, including the Omicron variant, in both HeLa-ACE2 cells and Vero-TMPRSS2 cells (Fig. 3B).


**Camostat and bafilomycin A1 synergistically inhibit SARS-CoV-2 entry.** Camostat has been shown to reach maximal blood concentrations of ~200 nM upon oral dosing (24, 26). Given the complete lack of protection seen for Camostat on cells lacking

#### FIG 1 Legend (Continued)

(niclosamide and oxyclozanide), and a specific V-ATPase inhibitor (bafilomycin A1). The highlighted tertiary ammonium cation of the lysosomotropic compounds is a characteristic structure of phospholipidosis-causing compounds. (B) Assays testing pseudoviral entry inhibition (left), endosomal acidification inhibition (top-right), and compound-mediated cell cytotoxicity (bottom-right) of each compound. (C) Comparison of inhibition of PsV entry, inhibition of endosomal acidification, and cell viability by each tested compound against HeLa-ACE2 cells. All experiments were conducted in triplicate, at the minimum, ( $n = 3$  to 14).




**FIG 2** Inhibition of endosomal acidification attenuates SARS-CoV-2 entry irrespective of TMPRSS2 expression. (A) Camostat and bafilomycin A1 were tested against SARS-CoV-2 PsVs using HeLa cells expressing ACE2 but lacking TMPRSS2 or Vero cells expressing both ACE2 and TMPRSS2. All experiments were conducted in at least  $n = 6$  up to  $n = 13$  ( $n = 6$  to  $13$ ). (B) Camostat and bafilomycin A1 were tested against authentic SARS-CoV-2 virus (MOI = 0.1) using Vero cells endogenously expressing ACE2 but lacking TMPRSS2 or Calu-3 cells endogenously expressing both ACE2 and TMPRSS2. Data represents three to four independent experiments each done in triplicate using SARS-CoV-2 (SARS-CoV-2/Canada/ON/VIDO-01/2020/Vero/76/p2 [Seq. available at GISAID – EPI\_ISL\_425177]) ( $n = 3$  to  $4$ ).



**FIG 3** Potency of host-dependent inhibition against different variants of SARS-CoV-2 remains unaffected. Camostat (A) and bafilomycin A1 (B) were tested against SARS-CoV-2 D614G, B.1.117 (i.e., Alpha), B.1.351 (i.e., Beta) or B.1.1.529 (i.e., Omicron) PsV variants using HeLa cells expressing ACE2 but lacking TMPRSS2 or Vero cells expressing both ACE2 and TMPRSS2. All experiments were conducted in quadruplicates, at the minimum ( $n = 4$  to 5). (C) The half-maximal inhibitory concentration (IC<sub>50</sub>) of Camostat and bafilomycin A1 against several SARS-CoV-2 PsVs variants using HeLa cells expressing ACE2 but lacking TMPRSS2 or Vero cells expressing both ACE2 and TMPRSS2 was calculated using Prism 9 (GraphPad). All experiments were conducted in quadruplicates, at the minimum ( $n = 4$  to 13).

TMPRSS2, and only partial protection seen in cells expressing TMPRSS2 (Fig. 2A), it would be predicted that Camostat would not provide complete blockade of viral entry *in vivo*. Previous studies on the related virus SARS-CoV found that simultaneous inhibition of the endosomal- and cell-surface-entry route was required for complete inhibition of viral entry (40). Therefore, we hypothesized that a combination of Camostat with bafilomycin A1 would inhibit both entry pathways and thus lead to the complete inhibition of SARS-CoV-2 entry. To this end, we tested two doses of bafilomycin A1 that inhibit viral entry (*viz.* 8.3 and 16.7 nM) in combination with a range of Camostat doses covering a full dose titration on Vero-TMPRSS2 cells and measured PsV entry (Fig. 4A). Across all doses of Camostat, both doses of bafilomycin A1 significantly increased the inhibition of PsV entry into TMPRSS2-expressing cells compared to Camostat alone.

The addition of 8.33 nM bafilomycin A1 to 104 nM Camostat drastically improved neutralization of SARS-CoV-2 beyond what would be expected if the two compounds inhibited additively (Fig. 4B). In view of these results, we explored whether the simultaneous inhibition of the two entry mechanisms of SARS-CoV-2 using Camostat and bafilomycin A1 could synergistically inhibit viral entry. To assess this and following a checkerboard assay format, we employed the Zero Interaction Potency (ZIP) model which combines the Bliss independence



**FIG 4** Host-dependent dual-entry inhibition safely and synergistically inhibits SARS-CoV-2 pseudovirus entry into mammalian cells. (A) A dose-dependent inhibition of SARS-CoV-2 PsV entry into Vero cells expressing both ACE2 and TMPRSS2 was measured using Camostat alone or Camostat in addition to either 8 nM or 17 nM bafilomycin A1. The blue box highlights the maximal blood concentration Camostat was found to achieve in patients (26). All experiments were conducted in duplicate ( $n = 2$ ). (B) 104 nM Camostat and 8 nM bafilomycin A1 were tested individually or in combination against SARS-CoV-2 PsVs using Vero cells expressing both ACE2 and TMPRSS2. The highlighted gray bar in the combination experiment highlights the theoretical neutralization if the two compounds acted additively. All experiments were conducted in duplicate ( $n = 2$ ). (C) A checkerboard assay using Camostat and bafilomycin A1 was conducted against SARS-CoV-2 PsV using Vero cells expressing both ACE2 and TMPRSS2. The experiments were conducted in duplicate ( $n = 2$ ). (D) A Zero Interaction Potency (ZIP) score of the checkerboard assay using Camostat and bafilomycin A1 from (C) was calculated using SynergyFinder 2.0. (E) A checkerboard assay using Camostat and bafilomycin A1 at the same concentrations as (C) on Vero cells expressing both ACE2 and TMPRSS2 was tested for compound-mediated toxicity. The experiment was conducted in triplicate ( $n = 3$ ).

model and the Loewe additivity model (41). The Bliss independence model assumes each compound elicits its effect independently, while the Loewe additivity model assumes both compounds are the same and thus the activity must be double when two compounds are combined at equal ratios. Hence, combined, the ZIP model identifies potential synergy between two compounds by comparing the change in potency of each compound with



different combinations. A ZIP synergy score  $>10$  has been proposed as a threshold indicative of synergistic inhibition by two compounds (41). Using this analysis, we observed that a combination of 104 nM Camostat and either 2.08 nM, 4.16 nM, 8.33 nM, or 16.67 nM bafilomycin A1 had a synergy score of 23.2, 28.5, 34.7, and 15.6, respectively. At 8.33 nM bafilomycin A1, the synergy score was  $>16$  as the concentration of Camostat increased from 104 nM to 833 nM indicating that this combination is highly synergistic at inhibiting PsV entry into Vero-TMPRSS2 cells (Fig. 4D). In addition, the data show that neither Camostat nor bafilomycin A1 alone fully inhibited PsV entry even at the highest concentrations tested (3333 nM and 66.7 nM, respectively) but, when combined, the two compounds provided complete inhibition (Fig. 4C). Importantly, none of the combinations had a toxic effect on Vero-TMPRSS2 cells (Fig. 4E). Taken together, by simultaneously blocking without cytotoxicity both entry mechanisms using Camostat and bafilomycin A1, SARS-CoV-2 is completely inhibited in a synergistic manner from infecting mammalian cells.

## DISCUSSION

The prospect of novel SARS-CoV-2 variants of concern emerging that are more transmissible and/or are resistant to the antibodies raised by natural infection, through vaccination or developed as therapeutics underscores the need for developing antivirals acting through distinct mechanisms (6–9). Promising phase III clinical trial data from Pfizer's Paxlovid and Merck's Molnupiravir have demonstrated the potential of small molecule therapeutics against SARS-CoV-2 (12, 13); however, it remains to be seen whether resistance against these virus targeted compounds will emerge (42). An alternative strategy to block the virus life cycle is to target the host factors and host mechanisms that are required for SARS-CoV-2 infection. This strategy has the added benefit of being resilient to SARS-CoV-2 mutations since the likelihood of drug resistance against a host-dependent mechanism is negligible without substantial changes to the S protein structure and function (43). Here, we focused on the major categories of host proteases implicated in the two distinct viral entry routes used by SARS-CoV-2: (i) the cell-surface route (mediated by TMPRSS2 found in some but not all cells) and (ii) the endosomal route (primarily mediated by cathepsin B and cathepsin L, found in all cells) (28). Because endosomal cathepsins require the low pH of acidified endosomal compartments for activation, it has been recognized that agents that raise the pH of endosomes can indirectly inhibit both cathepsin B and cathepsin L (27).

In the present study, we screened a panel of prototypic inhibitors of endosomal acidification that act through three distinct mechanisms to identify the most efficacious means to inhibit viral entry across multiple cellular contexts. Given recent reports of confounding toxicities for a subset of molecules that inhibit endosomal pH as part of their mechanism (35), together with a lack of clinical efficacy seen for molecules like hydroxychloroquine (a lysosomotropic molecule) (33, 34), we measured in parallel the extent to which each of the molecules tested induced cellular toxicity. We found that both lysosomotropic compounds (amodiaquine, chloroquine, and quinacrine) and a compound capable of shuttling protons out of the endosome (niclosamide) were cytotoxic at doses perceived to be effective at neutralizing viral entry. In contrast, we found that inhibition of endosomal acidification through a specific V-ATPase inhibitor (bafilomycin A1) was safe and effective at neutralizing SARS-CoV-2 entry into cells. The larger safety window of bafilomycin A1 minimally suggests that not all modes of inhibiting endosomal acidification are equal but more importantly demonstrates that the concomitant cytotoxicity of all other compounds confounds their further use to understand how SARS-CoV-2 is neutralized. Importantly, in support of this mechanism being important for viral entry, Daniloski et al., and others, used CRISPR (clustered regulatory interspaced short palindromic repeats) knockout screens to demonstrate that the disruption of the V-ATPase or endosomal acidification pathway results in protection against SARS-CoV-2 infection of mammalian cells (44, 45).

In contrast to Camostat, which only protects cells expressing TMPRSS2, we found that bafilomycin A1 was active in all cell lines tested irrespective of TMPRSS2 expression.

These results emphasize the importance of the endosomal pathway in the cell entry of SARS-CoV-2, a mechanism previously suggested not to be important in the presence of TMPRSS2 (32). These contradictory findings might be due, at least in part, to the cytotoxicity associated with compounds such as chloroquine or hydroxychloroquine that have been previously used to elucidate the importance of endosomal acidification for the entry of SARS-CoV-2. Indeed, their compound-mediated toxicity and different modes of inhibiting SARS-CoV-2 propagation makes it difficult to delineate the importance of endosomal acidification on viral entry (46–48). Further, recent work by Tummino et al. demonstrated that cationic amphiphilic compounds, such as chloroquine, induce phospholipidosis at efficacious doses underscoring the need for careful assessment of off-target toxicity of compounds with multiple modes of action (35). Taken together, safely and specifically inhibiting endosomal acidification using bafilomycin A1 blocks viral entry into mammalian cells irrespective of TMPRSS2 expression.

A recent report has demonstrated a decreased reliance on TMPRSS2 and a concurrent increased dependence on the endosomal route of entry by the Omicron variant, compared to other variants such as Delta (25). This shift highlights both the importance of the endosomal route of entry and the need for an antiviral drug strategy that will remain effective as SARS-CoV-2 continues to mutate and evolve. In line with these findings, Camostat was able to inhibit most of the tested variants with a similar efficacy compared to the wild type virus using Vero-TMPRSS2 cells but was unable to inhibit viral entry of the Omicron variant. More importantly, we found that bafilomycin A1 inhibited all tested variants with a similar efficacy compared to the wild-type pseudovirus, and did so irrespective of TMPRSS2 expression. The improved potency of bafilomycin A1 against the Omicron variant may be due to the variant's preference on the endosomal route of entry over other methods. Therefore, targeting endosomal acidification specifically appears to be the strategy by which multiple variants of concern are potentially inhibited.

Here, we show that a combination of Camostat and bafilomycin A1 fully inhibit viral entry in TMPRSS2-expressing cells in a synergistic manner and without cytotoxicity. In a recent clinical trial, Camostat was shown to be tolerable at oral doses which can achieve a blood concentration of ~200 nM (26). Unfortunately, Camostat on its own was shown to be ineffective at protecting against SARS-CoV-2 infections and bafilomycin A1 has yet to be progressed to a clinical trial as a single compound treatment. Our study identifies a new modality that should be explored in future experiments where a cell-surface inhibitor and endosomal route inhibitor are simultaneously used to protect against SARS-CoV-2 infections. Supporting this idea, Yuan et al. demonstrate the power of using two inhibitors targeting different mechanisms of the SARS-CoV-2 life cycle to synergistically inhibit SARS-CoV-2 infection *in vivo* (49). Importantly, inhibition of the endosomal route of entry, using bafilomycin A1, equally neutralized all variants tested. Our results suggest that the use of such inhibitors targeted at host-dependent mechanisms may be resilient against emerging variants of concern, and capable of broadly blocking viral entry into mammalian cells.

## MATERIALS AND METHODS

**High-throughput screen of endosomal acidification.** Inhibition of endosomal acidification was measured using LysoTracker Red DND-99 (ThermoFisher). Vero cells (ATCC) were seeded in 96-well clear CellBind plates (Sigma-Aldrich) 24 h prior to the experiment at a density of 40,000 cells/well in a 100  $\mu$ L volume of complete DMEM supplemented with 10% inactive FBS and 1% of penicillin/streptomycin. On the day of the experiment, the medium was replaced with 100  $\mu$ L of serum free DMEM. A volume of 0.4  $\mu$ L of each compound from the Spectrum Collection library (MicroSource), consisting of 2,560 individual compounds formatted as 10 mM solutions in DMSO, was incubated with the cells at 37°C for 2 h. Following this, 0.1  $\mu$ M final concentration of LysoTracker Red DND-99 (ThermoFisher) was added to each well and incubated for 30 min at 37°C. The cell medium was then replaced with 100  $\mu$ L of FluoroBrite DMEM (ThermoFisher). Fluorescence at excitation/emission 574/594 nm was measured using an Envision plate reader (Perkin Elmer). Data were plotted using Prism 9 (GraphPad).

**Pseudovirus production and neutralization assay.** HIV-1-derived viral particles were pseudotyped with full-length SARS-CoV-2 spike (S) protein as described previously (50). Briefly, plasmids expressing a lentiviral backbone encoding the luciferase reporter gene (BEI NR52516), the HIV structural and regulatory

proteins Tat (BEI NR52518), Gag-pol (BEI NR52517) and Rev (BEI NR52519), and the full-length SARS-CoV-2 S protein were co-transfected into human kidney HEK293T cells (ATCC, CRL-3216) using the BioT transfection reagent (Bioland Scientific) following the manufacturer's instructions. In order to test the effect of the S protein mutation D614G that renders a more infectious virus (8), the plasmid encoding the S protein containing the D614G mutation (kindly provided by D.R. Burton; The Scripps Research Institute) was used instead of the plasmid encoding the wild-type SARS-CoV-2 S protein. Similarly, the wild-type S plasmid was substituted with plasmids codifying for the B.1.117 or B.1.351 SARS-CoV-2 S proteins (kindly provided by David Ho, Columbia University) or B.1.1.529 (synthesized and cloned by GeneArt, LifeTechnologies into pcDNA3.4 expression vector) to generate the corresponding SARS-CoV-2 pseudoviral particle (PsV) variants. Transfected cells were incubated at 37°C and after 24 h, 5 mM sodium butyrate was added to the media. Cells were incubated for an additional 24 to 30 h at 30°C, after which PsVs were harvested, passed through 0.45  $\mu\text{m}$  pore sterile filters, and finally concentrated using a 100K Amicon Ultra 2.0 Centrifugal Filter Units (Merck Millipore Amicon).

Neutralization was determined in a single-cycle neutralization assay using HeLa cells expressing ACE2 (HeLa-ACE2), kindly provided by D.R. Burton; The Scripps Research Institute, and Vero E6 cells constitutively expressing the transmembrane protease, serine 2 (Vero-TMPRSS2), obtained from the Centre for AIDS Reagents (National Institute for Biological Standards and Control) (51, 52). Cells were seeded in 96-well clear CellBind plates (Sigma-Aldrich) 24 h prior to the experiment at a density of 10,000 cells/well in a 100  $\mu\text{L}$  volume. On the day of the experiment, the sample compounds were serially diluted in complete DMEM media (cDMEM<sup>2%</sup>) that contained 2% inactive fetal bovine serum (FBS) and 50  $\mu\text{g}/\text{mL}$  of gentamicin. Media from the cell culture was replaced with 100  $\mu\text{L}$  of fresh cDMEM<sup>2%</sup> media and 50  $\mu\text{L}$  of the previously diluted sample compounds were added to each well and incubated for 1 h at 37°C. After incubation, 50  $\mu\text{L}$  of PsVs was added to each well and incubated for 48 to 60 h in the presence of 10  $\mu\text{g}/\text{mL}$  of Polybrene (Sigma-Aldrich). Unless stated otherwise, PsV bearing the SARS-CoV-2 S protein (BEI NR52310) was used. PsV entry level was calculated based on luminescence in relative light units (RLUs). For that, 130  $\mu\text{L}$  of supernatant was aspirated from each well to leave approximately 50  $\mu\text{L}$  of media. 50  $\mu\text{L}$  Britelite plus reagent (PerkinElmer) was added to each condition and incubated for 2 min at room temperature. 100  $\mu\text{L}$  volume was transferred to a 96-well white plate (Sigma-Aldrich) and luminescence was read using a Synergy Neo2 Multi-Mode Assay Microplate Reader (Biotek Instruments). Data were plotted and half-maximal inhibitory concentration ( $\text{IC}_{50}$ ) values were calculated using Prism 9 (GraphPad).

In order to confirm that the reduced luminescence was not related to cell toxicity, HeLa-ACE2 and Vero-TMPRSS2 cell viability upon incubation with serial dilutions of the sample compounds were tested in parallel to the neutralization assay. Hence, following the above-mentioned protocol, 10,000 cells/well of pre-seeded cells were cocultured with the same serial dilutions of the sample compounds at 37°C for 48 to 60 h. Cell viability was monitored by adding 50  $\mu\text{L}$  of CellTiter-Glo reagent (Promega) to 200  $\mu\text{L}$  of media containing cells. After a 10-minute incubation, 100  $\mu\text{L}$  volume was transferred to a 96-well white plate (Sigma-Aldrich) to measure luminescence using a Synergy Neo2 Multi-Mode Assay Microplate Reader (Biotek Instruments). As an additional measure of cell toxicity Vero cell, lacking TMPRSS2, viability was measured using PrestoBlue (ThermoFisher). 10,000 cells/well of pre-seeded Vero cells were cocultured with the same serial dilutions of the sample compounds at 37°C for 48 h. At 48 h, 10  $\mu\text{L}$  of PrestoBlue (ThermoFisher) was added to 100  $\mu\text{L}$  of media containing cells. After a 2 h incubation, fluorescence was measured using a Spectromax m5e (Molecular Devices) at an excitation of 555 nm and emission of 585 nm. Data were plotted and half-cytotoxic concentration ( $\text{CC}_{50}$ ) values were calculated using Prism 9 (GraphPad).

Inhibition of endosomal acidification was measured using LysoTracker Red DND-99 (ThermoFisher). HeLa-ACE2 and Vero-TMPRSS2 cells were prepared following the above-mentioned protocol, where 10,000 cells/well of pre-seeded cells were cocultured with the same serial dilutions of the sample compounds at 37°C for 2 h. Following this, 0.1  $\mu\text{M}$  final concentration of LysoTracker Red DND-99 (ThermoFisher) was added to each well and incubated for 30 min at 37°C. The cell medium was then replaced with 100  $\mu\text{L}$  of FluoroBrite DMEM (ThermoFisher). Fluorescence was measured using a Synergy Neo2 Multi-Mode Assay Microplate Reader (Biotek Instruments) while employing a Texas Red filter. Data were plotted and  $\text{IC}_{50}$  values were calculated using Prism 9 (GraphPad).

**Authentic SARS-CoV-2 neutralization and titer assay.** Authentic SARS-CoV-2 experiments were conducted using Vero76 (ATCC, CRL-1587) or Calu-3 (ATCC, HTB-55) cells. Cells were seeded and grown in complete DMEM media (cDMEM) that contained 10% inactive FBS and 1% of penicillin/streptomycin overnight at 37°C to approximately 90% confluence in 96-well plates. SARS-CoV-2 (SARS-CoV-2/Canada/ON/VIDO-01/2020/Vero76/p2 [Seq. available at GISAID – EPI\_ISL\_425177]) virus was diluted in complete DMEM supplemented with 2% inactive FBS and 1% of penicillin/streptomycin to obtain a multiplicity of infection (MOI) of 0.1 (approximately 2000 TCID<sub>50</sub>/well). Two test compounds, Camostat and bafilomycin A1, were prepared to a 3-fold dilution in DMEM supplemented with 2% inactive FBS. Cells were incubated with the test compounds for 1 h prior to infection at which point 50  $\mu\text{L}$  of viral inoculum was added to each well. After 1 h of incubation with the viral inoculum, the inoculum and compound mixture were removed, and fresh compounds were added to the plate. The plates were incubated for 48 h at 37°C. At 24 h, plates were assessed for contamination. Media alone and cell-alone control wells (without viral infection and without compound treatment) were used as controls for virus replication.

The plate of infected cells that had been exposed to the test compounds was examined for cytopathic effect (CPE) and cytotoxicity (if noticeable) under a microscope at 48 h. At 48 h, 100  $\mu\text{L}$  of supernatant from each well was transferred into 96-well rounded-bottom plates. Viral titration by the median tissue culture infectious dose (TCID<sub>50</sub>) assay of the supernatant was carried out by a serial 7-fold dilution.

These dilutions were used to infect pre-seeded cells, as described for the initial infection. Cells were observed for CPE at 1, 3 and 5 days after the infection. The Spearman-Kärber algorithm were used to calculate TCID<sub>50</sub> titers which were used to calculate IC<sub>50</sub> values for each compound using Prims 9 (GraphPad).

**Pseudovirus neutralization synergy assay.** Synergistic neutralization by a combination of two compounds was defined as an increase in the inhibition of PsV entry upon the combination of two different compounds in comparison to the sum of the expected inhibition of both molecules or double the concentration of the best molecule in the *in vitro* assay (41). Hence, different ratios of the two compounds were mixed and serial dilutions were prepared in a total volume of 50  $\mu$ L for each condition using a checkerboard assay. The assay was performed using Vero-TMPRSS2 cells following the above protocol. The level of inhibition of each condition was calculated and compared to the expected values using the Zero Interaction Potency (ZIP) synergy score model (41). Synergy scores were assigned for each condition and values above 10 were interpreted as a synergistic effect.

In order to confirm that a combination of two compounds did not also lead to increased cell toxicity Vero-TMPRSS2 cell viability was measured using CellTiter-Glo reagent (Promega). Vero-TMPRSS2 cells were seeded overnight at 10,000 cells/well in 96-well clear CellBind plates (Sigma-Aldrich). Media was exchanged with 100  $\mu$ L of serum-free DMEM containing 1% penicillin-streptomycin. An Agilent Bravo liquid handler was used to deliver 0.27  $\mu$ L of bafilomycin A1 then 0.27  $\mu$ L of Camostat to the cell plates. The cell plates were incubated at 37°C for 48 to 60 h before 50  $\mu$ L of CellTiter-Glo reagent (Promega) was added. Cell plates were gently mixed at room temperature for 10 min then 100  $\mu$ L of the mixture was transferred to 96-well white plates to measure luminescence using a SpectraMax M5 (Molecular Devices). Data were plotted using Prism 9 (GraphPad).

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**SUPPLEMENTAL FILE 1**, PDF file, 0.7 MB.

## ACKNOWLEDGMENTS

This research was funded (S.I. and R.A.M.) from Fast Grants, part of the Emergent Ventures Program at the Mercatus Centre at George Mason University, with support from Thistledown Foundation. This research was supported by the European Union's Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant 790012 (E.R.). This work was further supported by the CIFAR Azrieli Global Scholar program (J.-P.J.), the Ontario Early Researcher Award program (J.-P.J.) and the Canada Research Chair program (J.-P.J.). The Synergy Neo2 Multi-Mode Assay Microplate Reader instrument was accessed at the Structural and Biophysical Core Facility, The Hospital for Sick Children, supported by the Canada Foundation for Innovation and Ontario Research Fund.

## REFERENCES

1. Coronaviridae Study Group of the International Committee on Taxonomy of V. 2020. Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* 5:536–544. <https://doi.org/10.1038/s41564-020-0695-z>.
2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 579:270–273. <https://doi.org/10.1038/s41586-020-2012-7>.
3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team. 2020. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 382:727–733. <https://doi.org/10.1056/NEJMoa2001017>.
4. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y, Yuan M-L, Zhang Y-L, Dai F-H, Liu Y, Wang Q-M, Zheng J-J, Xu L, Holmes EC, Zhang Y-Z. 2020. A new coronavirus associated with human respiratory disease in China. *Nature* 579:265–269. <https://doi.org/10.1038/s41586-020-2008-3>.
5. Coronavirus disease (COVID-19) pandemic. 2021. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.
6. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O. 2021. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* 596:276–280. <https://doi.org/10.1038/s41586-021-03777-9>.
7. Yurkovetskiy L, Wang X, Pascal KE, Tomkins-Tinch C, Nyalile TP, Wang Y, Baum A, Diehl WE, Dauphin A, Carbone C, Veinotte K, Egri SB, Schaffner SF, Lemieux JE, Munro JB, Rafique A, Barve A, Sabeti PC, Kyrtasous CA, Dudkina NV, Shen K, Luban J. 2020. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. *Cell* 183:739–751.e8. <https://doi.org/10.1016/j.cell.2020.09.032>.
8. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC, Sheffield COVID-19 Genomics Group. 2020. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 Virus. *Cell* 182:812–827.e19. <https://doi.org/10.1016/j.cell.2020.06.043>.
9. Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH, CMMID COVID-19 Working Group. 2021. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. *Nature* 593:270–274. <https://doi.org/10.1038/s41586-021-03426-1>.
10. Bates TA, Leier HC, Lyski ZL, McBride SK, Coulter FJ, Weinstein JB, Goodman JR, Lu Z, Siegel SAR, Sullivan P, Strnad M, Brunton AE, Lee DX, Adey AC, Bimber BN, O'Roak BJ, Curlin ME, Messer WB, Tafesse FG. 2021.

- Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. *Nat Commun* 12:5135. <https://doi.org/10.1038/s41467-021-25479-6>.
11. Kumar S, Chandele A, and Sharma A. 2021. Current status of therapeutic monoclonal antibodies against SARS-CoV-2. *PLoS Pathog* 17:e1009885. <https://doi.org/10.1371/journal.ppat.1009885>.
  12. Pfizer. 2021. Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.
  13. Merck. 2021. Merck and Ridgeback's investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study.
  14. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen K-Y, Wang Q, Zhou H, Yan J, Qi J. 2020. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. *Cell* 181:894–904. <https://doi.org/10.1016/j.cell.2020.03.045>.
  15. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. 2020. Structural basis of receptor recognition by SARS-CoV-2. *Nature* 581:221–224. <https://doi.org/10.1038/s41586-020-2179-y>.
  16. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, Müller MA, Drosten C, Pöhlmann S. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 181:271–280. <https://doi.org/10.1016/j.cell.2020.02.052>.
  17. Zhao MM, et al. 2021. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. *Signal Transduct Target Ther* 6:134. <https://doi.org/10.1038/s41392-021-00558-8>.
  18. Pišlar A, Mitrović A, Sabotić J, Pečar Fonović U, Perišić Nanut M, Jakoš T, Senjor E, Kos J. 2020. The role of cysteine peptidases in coronavirus cell entry and replication: the therapeutic potential of cathepsin inhibitors. *PLoS Pathog* 16:e1009013. <https://doi.org/10.1371/journal.ppat.1009013>.
  19. Hashimoto R, Sakamoto A, Deguchi S, Yi R, Sano E, Hotta A, Takahashi K, Yamanaka S, Takayama K. 2021. Dual inhibition of TMPRSS2 and Cathepsin B prevents SARS-CoV-2 infection in iPS cells. *Mol Ther Nucleic Acids* 26:1107–1114. <https://doi.org/10.1016/j.omtn.2021.10.016>.
  20. Bayati A, Kumar R, Francis V, McPherson PS. 2021. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. *J Biol Chem* 296:100306. <https://doi.org/10.1016/j.jbc.2021.100306>.
  21. Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM, Rawson S, Rits-Volloch S, Chen B. 2020. Distinct conformational states of SARS-CoV-2 spike protein. *Science* 369:1586–1592. <https://doi.org/10.1126/science.abd4251>.
  22. Delorey TM, Ziegler CGK, Heimberg G, Normand R, Yang Y, Segerstolpe Å, Abbondanza D, Fleming SJ, Subramanian A, Montoro DT, Jagadeesh KA, Dey KK, Sen P, Slyper M, Pita-Juárez YH, Phillips D, Biermann J, Bloom-Ackermann Z, Barkas N, Ganna A, Gomez J, Melms JC, Katsy I, Normandin E, Naderi P, Popov YV, Raju SS, Niezen S, Tsai LT-Y, Siddle KJ, Sud M, Tran VM, Vellarikal SK, Wang Y, Amir-Zilberstein L, Atri DS, Beecham J, Brook OR, Chen J, Divakar P, Dorceus P, Engreitz JM, Essene A, Fitzgerald DM, Fropf R, Gazal S, Gould J, Grzyb J, Harvey T, Hecht J, et al. 2021. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. *Nature* 595:107–113. <https://doi.org/10.1038/s41586-021-03570-8>.
  23. Murgolo N, Therien AG, Howell B, Klein D, Koeplinger K, Lieberman LA, Adam GC, Flynn J, McKenna P, Swaminathan G, Hazuda DJ, Olsen DB. 2021. SARS-CoV-2 tropism, entry, replication, and propagation: considerations for drug discovery and development. *PLoS Pathog* 17:e1009225. <https://doi.org/10.1371/journal.ppat.1009225>.
  24. Hoffmann M, Hofmann-Winkler H, Smith JC, Krüger N, Arora P, Sørensen LK, Søgaard OS, Hasselström JB, Winkler M, Hempel T, Raich L, Olsson S, Danov O, Jonig D, Yamazoe T, Yamatsuta K, Mizuno H, Ludwig S, Noé F, Kjolby M, Braun A, Shelton JM, Pöhlmann S. 2021. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. *EBioMedicine* 65:103255. <https://doi.org/10.1016/j.ebiom.2021.103255>.
  25. Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, Yamasoba D, Gerber PP, Fatihi S, Rathore S, Zepeda SK, Papa G, Kemp SA, Ikeda T, Toyoda M, Tan TS, Kuramochi J, Mitsunaga S, Ueno T, Shirakawa K, Takaori-Kondo A, Brevini T, Mallery DL, Charles OJ, Baker S, Dougan G, Hess C, Kingston N, Lehner PJ, Lyons PA, Matheson NJ, Ouwehand WH, Saunders C, Summers C, Thaventhiran JED, Toshner M, Weekes MP, Maxwell P, Shaw A, Bucke A, Calder J, Canna L, Domingo J, Elmer A, Fuller S, Harris J, Hewitt S, Kennet J, Jose S, Kourampa J, The CITIID-NIHR BioResource COVID-19 Collaboration, et al. 2022. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. *Nature* 603:706–714. <https://doi.org/10.1038/s41586-022-04474-x>.
  26. Gunst JD, Staerke NB, Pahus MH, Kristensen LH, Bodilsen J, Lohse N, Dalgaard LS, Brønnum D, Frøbert O, Hønge B, Johansen IS, Monrad I, Erikstrup C, Rosendal R, Vilstrup E, Mariager T, Bove DG, Offersen R, Shakar S, Cajander S, Jørgensen NP, Sriharan SS, Breining P, Jespersen S, Mortensen KL, Jensen ML, Kolte L, Frattari GS, Larsen CS, Storgaard M, Nielsen LP, Tolstrup M, Sædder EA, Østergaard LJ, Ngo HTT, Jensen MH, Højen JF, Kjolby M, Søgaard OS. 2021. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with COVID-19—a double-blind randomized controlled trial. *EclinicalMedicine* 35:100849. <https://doi.org/10.1016/j.eclinm.2021.100849>.
  27. Uhlman A, Folkers K, Liston J, Pancholi H, Hinton A. 2017. Effects of vacuolar H(+)-ATPase inhibition on activation of cathepsin B and cathepsin L secreted from MDA-MB231 breast cancer cells. *Cancer Microenviron* 10:49–56. <https://doi.org/10.1007/s12307-017-0196-7>.
  28. Vidak E, Javoršek U, Vizovišek M, Turk B. 2019. Cysteine cathepsins and their extracellular roles: shaping the microenvironment. *Cells* 8:264. <https://doi.org/10.3390/cells8030264>.
  29. Simmons G, Bertram S, Glowacka I, Steffen I, Chaipan C, Agudelo J, Lu K, Rennekamp AJ, Hofmann H, Bates P, Pöhlmann S. 2011. Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion. *Virology* 413:265–274. <https://doi.org/10.1016/j.virol.2011.02.020>.
  30. Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S. 2013. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. *Antiviral Res* 100:605–614. <https://doi.org/10.1016/j.antiviral.2013.09.028>.
  31. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov* 6:16. <https://doi.org/10.1038/s41421-020-0156-0>.
  32. Hoffmann M, Mösbauer K, Hofmann-Winkler H, Kaul A, Kleine-Weber H, Krüger N, Gassen NC, Müller MA, Drosten C, Pöhlmann S. 2020. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. *Nature* 585:588–590. <https://doi.org/10.1038/s41586-020-2575-3>.
  33. Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin RM, Files DC, Gibbs KW, Ginde AA, Gong MN, Harrell FE, Hayden DL, Hough CL, Johnson NJ, Khan A, Lindsell CJ, Matthay MA, Moss M, Park PK, Rice TW, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Ulysse CA, Weissman A, Yealy DM, Thompson BT, Brown SM, Steingrub J, Smithline H, Tiru B, Tidswell M, Kozikowski L, Thornton-Thompson S, De Souza L, Hou P, Baron R, Massaro A, Aisiku I, Fredenburgh L, Seethala R, Johnsky L, Riker R, Seder D, May T, National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, et al. 2020. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. *JAMA* 324:2165–2176. <https://doi.org/10.1001/jama.2020.22240>.
  34. Administration, U.S.F.a.D. 2020. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine, U.S.F.a.D. Administration, Editor.
  35. Tummino TA, Rezelj VV, Fischer B, Fischer A, O'Meara MJ, Monel B, Vallet T, White KM, Zhang Z, Alon A, Schadt H, O'Donnell HR, Lyu J, Rosales R, McGovern BL, Rathnasinghe R, Jangra S, Schotsaert M, Galarneau J-R, Krogan NJ, Urban L, Shokat KM, Kruse AC, García-Sastre A, Schwartz O, Moretti F, Vignuzzi M, Pognan F, Shoichet BK. 2021. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. *Science* 373:541–547. <https://doi.org/10.1126/science.abi4708>.
  36. Rujas E, Kucharska I, Tan YZ, Benlekbir S, Cui H, Zhao T, Wasney GA, Budylowski P, Guvenc F, Newton JC, Sicard T, Semesi A, Muthuraman K, Nouanesengsy A, Aschner CB, Prieto C, Bueler SA, Youssef S, Liao-Chan S, Glanville J, Christie-Holmes N, Mubareka S, Gray-Owen SD, Rubinstein JL, Treanor B, Julien J-P. 2021. Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. *Nat Commun* 12:3661. <https://doi.org/10.1038/s41467-021-23825-2>.
  37. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun* 11:1620. <https://doi.org/10.1038/s41467-020-15562-9>.
  38. Li K, Meyerholz DK, Bartlett JA, McCray PB. 2021. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19. *mBio* 12:e0097021. <https://doi.org/10.1128/mBio.00970-21>.

39. Shuai H, Chan JF-W, Hu B, Chai Y, Yuen TT-T, Yin F, Huang X, Yoon C, Hu J-C, Liu H, Shi J, Liu Y, Zhu T, Zhang J, Hou Y, Wang Y, Lu L, Cai J-P, Zhang AJ, Zhou J, Yuan S, Brindley MA, Zhang B-Z, Huang J-D, To KK-W, Yuen K-Y, Chu H. 2022. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. *Nature* 603:693–699. <https://doi.org/10.1038/s41586-022-04442-5>.
40. Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G. 2015. Protease inhibitors targeting coronavirus and filovirus entry. *Antiviral Res* 116:76–84. <https://doi.org/10.1016/j.antiviral.2015.01.011>.
41. Ianevski A, Giri AK, and Aittokallio T. 2020. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. *Nucleic Acids Res* 48:W488–W493. <https://doi.org/10.1093/nar/gkaa216>.
42. Ledford H. 2021. COVID antiviral pills: what scientists still want to know. *Nature* 599:358–359. <https://doi.org/10.1038/d41586-021-03074-5>.
43. Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. 2018. Host-directed therapies for bacterial and viral infections. *Nat Rev Drug Discov* 17:35–56. <https://doi.org/10.1038/nrd.2017.162>.
44. Daniloski Z, Jordan TX, Wessels H-H, Hoagland DA, Kasela S, Legut M, Maniatis S, Mimitou EP, Lu L, Geller E, Danziger O, Rosenberg BR, Phatnani H, Smibert P, Lappalainen T, tenOever BR, Sanjana NE. 2021. Identification of required host factors for SARS-CoV-2 infection in human cells. *Cell* 184:92–105. <https://doi.org/10.1016/j.cell.2020.10.030>.
45. Zhu Y, Feng F, Hu G, Wang Y, Yu Y, Zhu Y, Xu W, Cai X, Sun Z, Han W, Ye R, Qu D, Ding Q, Huang X, Chen H, Xu W, Xie Y, Cai Q, Yuan Z, Zhang R. 2021. A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry. *Nat Commun* 12:961. <https://doi.org/10.1038/s41467-021-21213-4>.
46. Li X, Wang Y, Agostinis P, Rabson A, Melino G, Carafoli E, Shi Y, Sun E. 2020. Is hydroxychloroquine beneficial for COVID-19 patients? *Cell Death Dis* 11:512. <https://doi.org/10.1038/s41419-020-2721-8>.
47. Tichauer JE, Soto D, Andresen M. 2021. Characterization of the modulatory effect of hydroxychloroquine on ACE2 activity: new insights in relation to COVID-19. *BioMed Research International* 2021:6614000.
48. Prabhakara C, Godbole R, Sil P, Jahnavi S, Gulzar S-E-J, van Zanten TS, Sheth D, Subhash N, Chandra A, Shivaraj A, Panikulam P, U I, Nuthakki VK, Puthiyapurayil TP, Ahmed R, Najjar AH, Lingamallu SM, Das S, Mahajan B, Vemula P, Bharate SB, Singh PP, Vishwakarma R, Guha A, Sundaramurthy V, Mayor S. 2021. Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors. *PLoS Pathog* 17:e1009706. <https://doi.org/10.1371/journal.ppat.1009706>.
49. Yuan S, Yin X, Meng X, Chan JF-W, Ye Z-W, Riva L, Pache L, Chan CC-Y, Lai P-M, Chan CC-S, Poon VK-M, Lee AC-Y, Matsunaga N, Pu Y, Yuen C-K, Cao J, Liang R, Tang K, Sheng L, Du Y, Xu W, Lau C-Y, Sit K-Y, Au W-K, Wang R, Zhang Y-Y, Tang Y-D, Clausen TM, Pihl J, Oh J, Sze K-H, Zhang AJ, Chu H, Kok K-H, Wang D, Cai X-H, Esko JD, Hung IF-N, Li RA, Chen H, Sun H, Jin D-Y, Sun R, Chanda SK, Yuen K-Y. 2021. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. *Nature* 593:418–423. <https://doi.org/10.1038/s41586-021-03431-4>.
50. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA, Vesler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD. 2020. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. *Viruses* 12:513. <https://doi.org/10.3390/v12050513>.
51. Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, Nagata N, Sekizuka T, Katoh H, Kato F, Sakata M, Tahara M, Kutsuna S, Ohmagari N, Kuroda M, Suzuki T, Kageyama T, Takeda M. 2020. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A* 117:7001–7003. <https://doi.org/10.1073/pnas.2002589117>.
52. Nao N, Sato K, Yamagishi J, Tahara M, Nakatsu Y, Seki F, Katoh H, Ohnuma A, Shirogane Y, Hayashi M, Suzuki T, Kikuta H, Nishimura H, Takeda M. 2019. Consensus and variations in cell line specificity among human metapneumovirus strains. *PLoS One* 14:e0215822. <https://doi.org/10.1371/journal.pone.0215822>.